Evaluation of EVE peptidome presentation on B16 cell line and tumors

Cancer immunotherapies have greatly improved the treatment of several solid cancers, albeit a large fraction of the patients still does not benefit from such treatments. Personalized therapies are envisioned to lead to improved outcomes yet they have largely been leveraging neoepitopes arising from missense somatic mutations, and as such primarily patients with relatively high tumor mutational burden (TMB) are eligible. With the goal to enhance and broaden its application, we here submit our results regarding our murine B16 studies with a focus on endogenous viral elements (EVE) derived peptidome. We observe how external signal or tumor microenvironment can alter this tumor model EVE presentation, while also keeping a significant overlap of EVE ligands across all biological treatments.